• Je něco špatně v tomto záznamu ?

Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer

A. Buqué, N. Bloy, M. Perez-Lanzón, K. Iribarren, J. Humeau, JG. Pol, S. Levesque, L. Mondragon, T. Yamazaki, A. Sato, F. Aranda, S. Durand, A. Boissonnas, J. Fucikova, L. Senovilla, D. Enot, M. Hensler, M. Kremer, G. Stoll, Y. Hu, C. Massa, SC....

. 2020 ; 11 (1) : 3819. [pub] 20200730

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem, Research Support, U.S. Gov't, Non-P.H.S.

Perzistentní odkaz   https://www.medvik.cz/link/bmc20024868

Hormone receptor (HR)+ breast cancer (BC) causes most BC-related deaths, calling for improved therapeutic approaches. Despite expectations, immune checkpoint blockers (ICBs) are poorly active in patients with HR+ BC, in part reflecting the lack of preclinical models that recapitulate disease progression in immunocompetent hosts. We demonstrate that mammary tumors driven by medroxyprogesterone acetate (M) and 7,12-dimethylbenz[a]anthracene (D) recapitulate several key features of human luminal B HR+HER2- BC, including limited immune infiltration and poor sensitivity to ICBs. M/D-driven oncogenesis is accelerated by immune defects, demonstrating that M/D-driven tumors are under immunosurveillance. Safe nutritional measures including nicotinamide (NAM) supplementation efficiently delay M/D-driven oncogenesis by reactivating immunosurveillance. NAM also mediates immunotherapeutic effects against established M/D-driven and transplantable BC, largely reflecting increased type I interferon secretion by malignant cells and direct stimulation of immune effector cells. Our findings identify NAM as a potential strategy for the prevention and treatment of HR+ BC.

Caryl and Israel Englander Institute for Precision Medicine New York NY USA

Caryl and Israel Englander Institute for Precision Medicine New York NY USA Sandra and Edward Meyer Cancer Center New York NY USA

Department of Cancer Medicine Gustave Roussy Cancer Center Villejuif France

Department of Radiation Oncology Weill Cornell Medical College New York NY USA

Department of Radiation Oncology Weill Cornell Medical College New York NY USA Caryl and Israel Englander Institute for Precision Medicine New York NY USA Sandra and Edward Meyer Cancer Center New York NY USA Department of Dermatology Yale School of Medicine New Haven CT USA Université de Paris Paris France

Department of Radiation Oncology Weill Cornell Medical College New York NY USA Equipe labellisée par la Ligue contre le cancer Centre de Recherche des Cordeliers INSERM U1138 Université de Paris Sorbonne Université Paris France

Department of Radiation Oncology Weill Cornell Medical College New York NY USA Sandra and Edward Meyer Cancer Center New York NY USA

Equipe labellisée par la Ligue contre le cancer Centre de Recherche des Cordeliers INSERM U1138 Université de Paris Sorbonne Université Paris France

Equipe labellisée par la Ligue contre le cancer Centre de Recherche des Cordeliers INSERM U1138 Université de Paris Sorbonne Université Paris France Faculté de Médecine Université de Paris Sud Paris Saclay Le Kremlin Bicêtre Paris France Metabolomics and Cell Biology Platforms Gustave Roussy Comprehensive Cancer Institute Villejuif France

Equipe labellisée par la Ligue contre le cancer Centre de Recherche des Cordeliers INSERM U1138 Université de Paris Sorbonne Université Paris France Metabolomics and Cell Biology Platforms Gustave Roussy Comprehensive Cancer Institute Villejuif France

Equipe labellisée par la Ligue contre le cancer Centre de Recherche des Cordeliers INSERM U1138 Université de Paris Sorbonne Université Paris France Metabolomics and Cell Biology Platforms Gustave Roussy Comprehensive Cancer Institute Villejuif France Pôle de Biologie Hôpital Européen Georges Pompidou AP HP Paris France Suzhou Institute for Systems Medicine Chinese Academy of Medical Sciences Suzhou China Department of Women's and Children's Health Karolinska University Hospital Stockholm Sweden

Faculté de Médecine Université de Paris Sud Paris Saclay Le Kremlin Bicêtre Paris France Gustave Roussy Cancer Center Villejuif France INSERM U1015 Villejuif France Center of Clinical Investigations in Biotherapies of Cancer 1428 Villejuif France

Gustave Roussy Cancer Center Villejuif France

Institute of Medical Immunology Martin Luther University Halle Wittenberg Halle Germany

Sorbonne Université Inserm CNRS Centre d'Immunologie et des Maladies Infectieuses CIMI Paris France

Sotio Prague Czech Republic

Sotio Prague Czech Republic Department of Immunology Charles University 2nd Faculty of Medicine and University Hospital Motol Prague Czech Republic

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20024868
003      
CZ-PrNML
005      
20201222153558.0
007      
ta
008      
201125s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41467-020-17644-0 $2 doi
035    __
$a (PubMed)32732875
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Buqué, Aitziber $u Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA. Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.
245    10
$a Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer / $c A. Buqué, N. Bloy, M. Perez-Lanzón, K. Iribarren, J. Humeau, JG. Pol, S. Levesque, L. Mondragon, T. Yamazaki, A. Sato, F. Aranda, S. Durand, A. Boissonnas, J. Fucikova, L. Senovilla, D. Enot, M. Hensler, M. Kremer, G. Stoll, Y. Hu, C. Massa, SC. Formenti, B. Seliger, O. Elemento, R. Spisek, F. André, L. Zitvogel, S. Delaloge, G. Kroemer, L. Galluzzi,
520    9_
$a Hormone receptor (HR)+ breast cancer (BC) causes most BC-related deaths, calling for improved therapeutic approaches. Despite expectations, immune checkpoint blockers (ICBs) are poorly active in patients with HR+ BC, in part reflecting the lack of preclinical models that recapitulate disease progression in immunocompetent hosts. We demonstrate that mammary tumors driven by medroxyprogesterone acetate (M) and 7,12-dimethylbenz[a]anthracene (D) recapitulate several key features of human luminal B HR+HER2- BC, including limited immune infiltration and poor sensitivity to ICBs. M/D-driven oncogenesis is accelerated by immune defects, demonstrating that M/D-driven tumors are under immunosurveillance. Safe nutritional measures including nicotinamide (NAM) supplementation efficiently delay M/D-driven oncogenesis by reactivating immunosurveillance. NAM also mediates immunotherapeutic effects against established M/D-driven and transplantable BC, largely reflecting increased type I interferon secretion by malignant cells and direct stimulation of immune effector cells. Our findings identify NAM as a potential strategy for the prevention and treatment of HR+ BC.
650    _2
$a 9,10-dimethyl-1,2-benzanthracen $7 D015127
650    _2
$a zvířata $7 D000818
650    _2
$a nádory prsu $x imunologie $x metabolismus $x terapie $7 D001943
650    _2
$a karcinogeneze $x účinky léků $x imunologie $7 D063646
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunoterapie $x metody $7 D007167
650    _2
$a interferon typ I $x imunologie $x metabolismus $7 D007370
650    _2
$a experimentální nádory mléčných žláz $x chemicky indukované $x imunologie $x prevence a kontrola $7 D008325
650    _2
$a medroxyprogesteronacetát $7 D017258
650    _2
$a myši inbrední BALB C $7 D008807
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a myši knockoutované $7 D018345
650    _2
$a niacinamid $x aplikace a dávkování $7 D009536
650    _2
$a receptor erbB-2 $x imunologie $x metabolismus $7 D018719
650    _2
$a analýza přežití $7 D016019
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a Research Support, U.S. Gov't, Non-P.H.S. $7 D013486
700    1_
$a Bloy, Norma $u Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA. Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.
700    1_
$a Perez-Lanzón, Maria $u Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France. Faculté de Médecine, Université de Paris Sud, Paris-Saclay, Le Kremlin-Bicêtre, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
700    1_
$a Iribarren, Kristina $u Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
700    1_
$a Humeau, Juliette $u Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France. Faculté de Médecine, Université de Paris Sud, Paris-Saclay, Le Kremlin-Bicêtre, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
700    1_
$a Pol, Jonathan G $u Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
700    1_
$a Levesque, Sarah $u Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France. Faculté de Médecine, Université de Paris Sud, Paris-Saclay, Le Kremlin-Bicêtre, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
700    1_
$a Mondragon, Laura $u Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
700    1_
$a Yamazaki, Takahiro $u Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
700    1_
$a Sato, Ai $u Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
700    1_
$a Aranda, Fernando $u Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
700    1_
$a Durand, Sylvère $u Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
700    1_
$a Boissonnas, Alexandre $u Sorbonne Université, Inserm, CNRS, Centre d'Immunologie et des Maladies Infectieuses CIMI, Paris, France.
700    1_
$a Fucikova, Jitka $u Sotio, Prague, Czech Republic. Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Senovilla, Laura $u Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.
700    1_
$a Enot, David $u Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
700    1_
$a Hensler, Michal $u Sotio, Prague, Czech Republic.
700    1_
$a Kremer, Margerie $u Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
700    1_
$a Stoll, Gautier $u Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
700    1_
$a Hu, Yang $u Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA.
700    1_
$a Massa, Chiara $u Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.
700    1_
$a Formenti, Silvia C $u Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA. Sandra and Edward Meyer Cancer Center, New York, NY, USA.
700    1_
$a Seliger, Barbara $u Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle, Germany.
700    1_
$a Elemento, Olivier $u Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA. Sandra and Edward Meyer Cancer Center, New York, NY, USA.
700    1_
$a Spisek, Radek $u Sotio, Prague, Czech Republic. Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a André, Fabrice $u Gustave Roussy Cancer Center, Villejuif, France.
700    1_
$a Zitvogel, Laurence $u Faculté de Médecine, Université de Paris Sud, Paris-Saclay, Le Kremlin-Bicêtre, Paris, France. Gustave Roussy Cancer Center, Villejuif, France. INSERM U1015, Villejuif, France. Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France.
700    1_
$a Delaloge, Suzette $u Department of Cancer Medicine, Gustave Roussy Cancer Center, Villejuif, France.
700    1_
$a Kroemer, Guido $u Equipe labellisée par la Ligue contre le cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France. kroemer@orange.fr. Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France. kroemer@orange.fr. Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France. kroemer@orange.fr. Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China. kroemer@orange.fr. Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden. kroemer@orange.fr.
700    1_
$a Galluzzi, Lorenzo $u Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA. deadoc80@gmail.com. Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA. deadoc80@gmail.com. Sandra and Edward Meyer Cancer Center, New York, NY, USA. deadoc80@gmail.com. Department of Dermatology, Yale School of Medicine, New Haven, CT, USA. deadoc80@gmail.com. Université de Paris, Paris, France. deadoc80@gmail.com.
773    0_
$w MED00184850 $t Nature communications $x 2041-1723 $g Roč. 11, č. 1 (2020), s. 3819
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32732875 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222153554 $b ABA008
999    __
$a ok $b bmc $g 1599013 $s 1115554
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 11 $c 1 $d 3819 $e 20200730 $i 2041-1723 $m Nature communications $n Nat Commun $x MED00184850
LZP    __
$a Pubmed-20201125
Zpět

Najít záznam

Citační ukazatele

    Možnosti archivace